Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma [Clinical Trials]

Conclusion Single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory patients with PCNSL; however, responses were usually short lived.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Brain Tumors Clinical Trials Source Type: research